A democratized platform for mapping the spatial epigenome in tissue

项目总结 AtlasXology Inc.正在将下一代空间生物学工具商业化，以帮助 研究人员了解疾病的表观遗传机制。这笔SBIR赠款的目标是 将硬件、消耗品和软件的产品套件商业化，以在空间上询问 组织，并生成新的数据层，以更好地理解基因表达调控 组织。开发新的研究工具是解决重大医疗保健问题的关键 癌症和心血管疾病造成的负担。表观遗传失调对 在疾病发展和治疗反应中的作用，但目前的技术是不够的 用于捕捉相互作用的细胞群体的表观遗传变化。AtlasX组学公司开发并 已建立的空间ATAC-SEQ(转座酶测定)的概念验证性能 可及染色质)试验。在第一阶段，AtlasXEconomics成功地将学术 协议引入商业工作流程，并符合鼠标ATAC-SEQ质量的行业标准 和人类癌症组织。该公司推出了第一个商业表观基因组学检测方法 2022年6月的市场。 在这一拟议的第二阶段，公司将提高化验的性价比，以 解决客户和潜在客户的反馈：覆盖更大的组织区域，增加蜂窝 解决方案，并建立一个用户友好、交互的数据分析套件，使研究人员能够 无缝分析数据。这款SBIR的产品将是一款一体化套件，它集成了 一套硬件、消耗品和生物信息学工具，使科学家能够探索 疾病病理学的表观遗传学维度。例如，在空间上表征肿瘤和免疫细胞 在组织微环境中。该产品将使空间技术的广泛应用大众化 表观基因组学平台，因为它不需要昂贵的定制设备和拟议的 生物信息学工作流程还将简化对生成的大型表观基因组数据集的分析 通过化验。该产品将帮助科学家获得对空间表观遗传学的生物学洞察力 驱动疾病进展和治疗反应的机制。

PROJECT SUMMARY AtlasXomics Inc. is commercializing the next generation of spatial biology tools to help researchers understand the epigenetic mechanisms of disease. The goal of this SBIR grant is to commercialize a product suite of hardware, consumables, and software to spatially interrogate tissue and generate a new layer of data for better understanding gene expression modulation in tissue. The development of novel research tools is critical to address the significant healthcare burden posed by cancer and cardiovascular disease. Epigenetic dysregulation plays a significant role in disease development and response to therapy, but current technologies are inadequate for capturing epigenetic changes in interacting cell populations. AtlasXomics developed and established proof-of-concept performance of the spatial ATAC-seq (Assay for Transposase Accessible Chromatin) assay. In the Phase I, AtlasXomics successfully transferred the academic protocol into a commercial workflow and met industry standards for ATAC-seq quality in mouse and human cancer tissues. The Company introduced the first commercial epigenomics assay to the market in June 2022. In this proposed Phase II, the Company will increase the price performance of the assay to address feedback from customers and prospects: cover a larger area of tissue, increase cellular resolution, and establish a user-friendly, interactive data analysis suite that enables researchers to seamlessly analyze data. The product of this SBIR will be an all-in-one kit that integrates a suite of hardware, consumables, and bioinformatics tools to enable scientists to explore the epigenetic dimension of disease pathology., e.g., characterize tumor and immune cells spatially in the tissue microenvironment. The product will democratize broad adoption of the spatial epigenomics platform because it does not require costly custom equipment and the proposed bioinformatics workflow will also simplify the analysis of the large epigenomics datasets generated by the assay. This product will help scientists to gain biological insight into the spatial epigenetic mechanisms that drive disease progression and therapy response.